Skip to content
Peptide research

Testagen

Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

What it is

A synthetic four-amino-acid peptide marketed as a bioregulator for testosterone normalization and male reproductive support. The case rests on mechanistic and in vitro work from largely one research group, with essentially no independent human data behind the touted testosterone or thyroid effects. There is no formal human safety profile, and supply is unregulated research-grade product. Not an FDA-approved drug, with no established clinical indication.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Testosterone normalization and male reproductive support

    Speculative

    No direct evidence in any species; testosterone effect is inferred, not measured, mechanism only.

  • Thyroid hormone normalization and thyroid gland structural restoration

    Low

    Consistent animal studies show thyroid tissue and hormone recovery in birds; no human data yet.

  • Thymic immune tissue restoration

    Speculative

    Single animal study showed thymus tissue recovery on histology alone, no functional immune tests.

Evidence limits

Evidence Level
Preclinical

The clinical evidence for Testagen is extremely limited. Evidence for purified KEDG remains predominantly preclinical. Human reports concern commercial preparations, including Testoluten and an oral Testagen supplement studied in 36 men during 2010–2011. The latter compared adjunctive treatment with standard treatment and did not report blinding or chemical verification of pure KEDG. These reports do not establish efficacy or safety of injectable KEDG. The Testoluten report (Khavinson et al. 2006) involved 36 men aged 43-61, with 19 receiving active treatment, and showed a 26% testosterone increase over 10 days; it was not registered on any clinical trial registry, was not independently replicated, and was conducted entirely within Khavinson's research network. The remaining evidence is preclinical: avian models for thyroid effects (multiple studies by Kuznik et al.), cell culture for DNA/histone interaction (Fedoreyeva et al.), and in vitro rat testicular explant cultures. No Western clinical trials, no ClinicalTrials.gov registrations, and no independent verification of any clinical claims exist. The broader Khavinson peptide bioregulator program claims over 15 years of clinical use in Russia with favorable safety, but these results lack independent validation.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No formal human safety profile established

    High
  • All safety data from a single research group without independent verification

    High
  • Research-grade product quality and purity concerns

    High
  • Potential hormonal disruption

    Theoretical
  • Unknown long-term effects of epigenetic modulation

    Theoretical
  • Injection site reactions

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.